Clinical trials: Physical activity
Female Sexual Dysfunction
Evaluation of an Online Intervention for Female Sexual Dysfunction
In this randomized controlled clinical trial, 250 participants with female sexual dysfunction will be investigated regarding the effectiveness of an online intervention for improving sexual function, the unguided online…
- Trial name
- FELYCIA (NCT06237166)
- Testing
- mylovia
- Where
- Germany
- Volunteers
- 252 people
- Sponsor
- Gaia AG
Advanced Cancer
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK105 as a single agent in adult subjects with advanced solid tumor malignancies.
- Trial name
- NCT03352531
- Testing
- AK-105
- Where
- 5 sites in Australia
- Volunteers
- 99 people
- Sponsor
- Akesobio Australia Pty Ltd
Advanced Solid Tumor, Adult Disease
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Adult Disease, Lung Cancer
- Trial name
- ANV419-001 (NCT04855929)
- Testing
- ANV419, Ipilimumab
- Where
- 5 sites in Spain, Switzerland and 1 more
- Volunteers
- 55 people
- Sponsor
- Anaveon AG
Histologically or Cytologically Confirmed Advanced Solid Tumors
A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors
an open-label, multicenter, Phase I study designed to evaluate the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of SIM0532 in participants with advanced solid tumors.
- Trial name
- NCT07749703
- Testing
- SIM0532 Tablets
- Where
- 6 sites in China
- Volunteers
- 346 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Stress, Burnout
Evaluating the Effectiveness of a Digital Therapeutic (Reviga) for People With Stress or Burnout
In this single-blinded randomized controlled clinical trial 290 patients with stress or burnout will be investigated regarding the effectiveness of a digital therapeutic for improvement of stress level, the unguided online…
- Trial name
- LAVENDER (NCT05998161)
- Testing
- reviga
- Where
- Germany
- Volunteers
- 290 people
- Sponsor
- Gaia AG
Advanced Malignant Solid Tumors
A Phase I Study of JSKN021 in Advanced Solid Tumors
This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced…
- Trial name
- NCT07617727
- Testing
- JSKN021
- Where
- 10 sites in China
- Volunteers
- 199 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Atrophy, Vaginal Diseases
Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity
The purpose of this study is to determine the safety and efficacy of ospemifene in postmenopausal women experiencing moderate to severe vaginal dryness and vaginal pain associated with sexual activity.
- Trial name
- NCT00729469
- Testing
- Ospemifene 60 mg
- Volunteers
- 919 people
- Sponsor
- Shionogi
High-grade Glioma, WHO Grade Ⅳ Glioma
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.
This is a phase I, open-Label, single/multiple dose, dose-escalation study to evaluate the safety, tolerability and antitumor activity of anti-B7-H3 CAR-T cell injection (TX103) in subjects with recurrent or progressive Grade 4…
- Trial name
- NCT06482905
- Testing
- Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103
- Where
- 4 sites in United States, China
- Volunteers
- 52 people
- Sponsor
- Tcelltech Inc.
COVID-19
Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients
Study of ANA001 in Moderate and Severe COVID-19 Patients
- Trial name
- NCT04603924
- Testing
- Niclosamide
- Where
- 8 sites in United States
- Volunteers
- 49 people
- Sponsor
- NeuroBo Pharmaceuticals Inc.
Advanced Solid Tumor
A Study of BRY805 in Participants With Advanced Solid Tumors
This is a phase 1 open label multicenter study to evaluate safety, tolerance and the maximum tolerance of BRY805 administered intravenously (IV) once every three weeks in participants with advanced solid tumors, so as to confirm…
- Trial name
- NCT06289894
- Testing
- BRY805 injection
- Where
- China
- Volunteers
- 13 people
- Sponsor
- BioRay Pharmaceutical Co., Ltd.
Asthma, Exercise-Induced
Montelukast Compared With Placebo and Salmeterol in Exercise-Induced Bronchoconstriction (0476-316)
To determine the effect of an approved medication being studied in support of a new approach in the prevention of exercise-induced asthma (a worsening of asthma caused by exercise, also known as exercise-induced bronchospasm), in…
- Trial name
- NCT00245570
- Testing
- Comparator: Montelukast, Comparator: Salmeterol
- Volunteers
- 47 people
- Sponsor
- Organon and Co
Advanced Solid Tumors
GenSci143 in Participants With Advanced Solid Tumors
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors
- Trial name
- NCT07252414
- Testing
- GenSci143 for injection
- Where
- 13 sites in United States, China
- Volunteers
- 180 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
HIV-1 Infection
A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients
A double-blind, randomized, placebo-controlled, dose-escalating study to assess the antiviral activity, safety, tolerability, and pharmacokinetics (PK) of the CCR5 antagonist TBR 652 monotherapy dosed orally once daily (QD) for…
- Trial name
- NCT01092104
- Testing
- TBR-652, TBR-652 50 mg, TBR-652 75 mg
- Volunteers
- 52 people
- Sponsor
- Tobira Therapeutics, Inc.
Multiple Myeloma
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients
This is a randomized Phase III study to evaluate the efficacy and safety of perifosine when added to the combination of bortezomib and dexamethasone in multiple myeloma patients who have relapsed on a prior bortezomib treatment…
- Trial name
- NCT01002248
- Testing
- Perifosine, Bortezomib, Dexamethasone
- Where
- 86 sites in United States, Canada and 7 more
- Volunteers
- 135 people
- Sponsor
- AEterna Zentaris
Advanced/Metastatic HER2-positive Breast, Gastric, Gastroesophageal Junction Cancer With Disease Progression Following Anti-HER2 Standard of Care Treatment
A Study to Evaluate Safety, Tolerability, Dosimetry, and Preliminary Efficacy of the HER2 Directed Radioligand CAM-H2 in Patients With Advanced/Metastatic HER2-Positive Breast, Gastric, and Gastro-Esophageal Junction (GEJ) Cancer
This is a Phase 1/2 multi-center, open label, dose escalation and dose expansion study to evaluate safety, tolerability, dosimetry, pharmacodynamics (PD), and efficacy of the targeted radionuclide therapeutic CAM-H2 in patients…
- Trial name
- NCT04467515
- Testing
- CAM-H2
- Where
- 12 sites in United States, Canada
- Volunteers
- 13 people
- Sponsor
- Precirix
Advanced/Metastatic Solid Tumors
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
This open-label, two-part study is designed to assess the safety, PK, PD, and therapeutic activity of Selicrelumab in combination with vanucizumab or bevacizumab in participants with metastatic solid tumors not amenable to…
- Trial name
- NCT02665416
- Testing
- Selicrelumab, Vanucizumab, Bevacizumab
- Where
- 16 sites in United States, Belgium and 5 more
- Volunteers
- 94 people
- Sponsor
- Hoffmann-La Roche
Solid Tumors, Adult
HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor
This is a first-in-human, multicenter, open-label, phase I/Ⅱa clinical study of HMPL-A580 in participants with unresectable, advanced or metastatic solid tumors.
- Trial name
- NCT07396584
- Testing
- HMPL-A580
- Where
- 14 sites in United States, China
- Volunteers
- 186 people
- Sponsor
- Hutchmed
Heart Failure With Reduced Ejection Fraction
VAgal Nerve Stimulation: safeGUARDing Heart Failure Patients
The purpose of the VANGUARD study is to demonstrate the safety of Vagal Nerve Stimulation for the treatment of congestive heart failure with reduced ejection fraction, and to report secondary measures of efficacy.
- Trial name
- VANGUARD (NCT02113033)
- Testing
- Equilia® Vagal Nerve Stimulation
- Where
- 6 sites in Belgium, France and 2 more
- Volunteers
- 15 people
- Sponsor
- LivaNova
Erectile Dysfunction
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
Adult subjects with mild to moderate and moderate ED who meet the study eligibility criteria will be enrolled in the study. The enrolled subjects will be randomized by a 1:1 ratio to receive the Active or Sham VERTICA® treatment.
- Trial name
- NCT06167733
- Testing
- VERTICA Active device
- Where
- 6 sites in United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- OHH-MED Medical Ltd
Osteoarthritis, Knee
Safety Study of TissueGene-C in Degenerative Joint Disease of the Knee
The study is being conducted to investigate the safety and activity of TissueGene-C injected into the knee joint of patients with chronic degenerative joint disease (DJD) who will be undergoing total knee replacement.
- Trial name
- TGC-03-01 (NCT00599248)
- Testing
- TissueGene-C
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Kolon TissueGene, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.